# IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)

> **NCT06513429** · NA · RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 6 (estimated)

## Conditions studied

- Refractory Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** IM19 CAR-T cells

## Key facts

- **NCT ID:** NCT06513429
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-30
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2025-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06513429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06513429, "IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06513429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*